Cancer – ACNS1022: Phase 2 Randomized Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Condition or Therapy:
Neurofibromatosis, pilocytic astrocytoma
Cancer and Blood Disorders
Study Number: ACNS1022
What is the goal of this study?
This trial looks to see if patients with recurrent, refractory or progressive optic nerve pathway gliomas or juvenile pilocytic astrocytoma respond better to low dose or high dose lenalidomide.
Who can join the study?
This study may be a good fit for children and yound adults who:
- are up to 21 years old, and
- have refractory, progressive or relapsed optic pathway glioma or pilocytic astrocytoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.